Nephrology
Renal Transplantation
1
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Renal Transplantation is an early-stage landscape with 1 program across 4 companies. The most active players are Mario Negri Institute for Pharmacological Research, Neovii Biotech, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
72
clinical trials
Completed41 · 57%
Unknown status15 · 21%
Terminated11 · 15%
Active, not recruiting2 · 3%
Withdrawn2 · 3%
Recruiting1 · 1%
Clinical Trials
Trial Activity
72 trials
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
Recruiting·—·Phase 4·NCT05702931·104 enrolled
1 vs 7 RATG Infusions in Renal Transplantation
Active, not recruiting·
Mario Negri Institute for Pharmacological Research·N/A·NCT06374095·75 enrolled
Mario Negri Institute for Pharmacological Research·N/A·NCT06374095·75 enrolledSGLT2i in Diabetic Patients with Renal Transplantation
Active, not recruiting·—·Phase 1/2·NCT06731231·72 enrolled
The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation
Completed·—·Phase 3·NCT03018041·174 enrolled
Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation
Completed·—·Phase 4·NCT02083991·224 enrolled
TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic
Completed·—·Phase 4·NCT00552201·280 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)